Introduction {#Sec1}
============

Sepsis is a life-threatening condition caused by an injurious host response to infection with an estimated incidence of over 19 million cases per year worldwide \[[@CR1], [@CR2]\]. Sepsis plays a prominent role in patients admitted to intensive care units (ICUs) where it is highly associated with morbidity and mortality \[[@CR3]\]. During sepsis, triggering of inflammatory and coagulation cascades, together with endothelial damage, invariably leads to activation of platelets \[[@CR4], [@CR5]\]. Platelet activation can be further stimulated by direct interactions with pathogens \[[@CR4], [@CR6]\]. Platelets are essential components of primary hemostasis and in addition can aid the host in eliminating invading pathogens by facilitating a variety of bactericidal effector mechanisms \[[@CR4], [@CR6], [@CR7]\]. However, during uncontrolled infection platelet activation contributes to sepsis complications \[[@CR4], [@CR8]\]. Indeed, several preclinical studies have shown beneficial effects of antiplatelet therapy in sepsis models \[[@CR4]\].

Antiplatelet drugs such as clopidogrel or acetylsalicyclic acid are widely used in the secondary prevention of cardiovascular, cerebrovascular, and peripheral arterial thrombosis. To date, there has been no randomized controlled clinical trial investigating the effect of antiplatelet therapy in sepsis. Retrospective studies showed a beneficial effect of pre-existing therapy with an antiplatelet drug with respect to organ failure, duration of ICU and hospital stay, and mortality in critically ill patients \[[@CR4], [@CR8], [@CR9]\]. However, most studies in critically ill patients with infection were small and/or included patient groups that were not matched for potential confounding factors, such as comorbidity and other chronic medication. In addition, the effect of antiplatelet therapy on the host response to critical illness has not been studied in patients.

The aim of the present prospective observational study was to determine the association between pre-existing antiplatelet therapy and presentation and outcome of sepsis, and induction of biomarkers providing insight into hallmark host responses, making use of a large well-defined cohort of patients admitted to the ICU. We hypothesized that chronic antiplatelet therapy may improve sepsis outcome by mitigating the derailed host response.

Methods {#Sec2}
=======

Study design, patients, and definitions {#Sec3}
---------------------------------------

This study was conducted as part of the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) project, a prospective observational study in the mixed ICUs of two tertiary teaching hospitals (Academic Medical Center in Amsterdam and University Medical Center Utrecht) in the Netherlands between January 2011 and January 2014 (ClinicalTrials.gov identifier NCT01905033) \[[@CR10], [@CR11]\]. Both ICUs comply with the Surviving Sepsis Guidelines \[[@CR12]\]. Dedicated observers prospectively collected the following data from all patients: demographics, comorbidities (including the Charlson comorbidity index \[[@CR13]\]), chronic medication use, ICU admission characteristics (including the Acute Physiology and Chronic Health Evaluation (APACHE) IV score and the acute physiology score \[[@CR14]\]), and daily physiological measurements, severity scores (including Sequential Organ Failure Assessment (SOFA) scores \[[@CR15]\]), and culture results. Organ failure was defined as a SOFA score of 3 or greater, except for cardiovascular failure for which a score of 1 or more was used \[[@CR16]\]. Shock was defined as the use of vasopressors (noradrenaline) for hypotension in a dose of 0.1 μg/kg/min during at least 50 % of the ICU day. The plausibility of infection was post hoc scored on the basis of all available evidence and classified on a 4-point scale (*none*,*possible*,*probable*, or*definite*) according to Centers for Disease Control and Prevention \[[@CR17]\] and International Sepsis Forum consensus definitions \[[@CR18]\], as described in detail previously \[[@CR10]\]. Daily (at admission and at 6 A.M. thereafter) left-over plasma (obtained from blood drawn for patient care) was stored within 4 h at −80 °C. The medical ethical committees of both study centers gave approval for an opt-out consent method (IRB no. 10-056C). The Municipal Personal Records Database was consulted to determine survival up to 1 year after ICU admission.

For the current analysis we selected all patients included in the MARS study between January 2011 and July 2013 with sepsis, diagnosed within 24 h after admission, defined as a *definite* or *probable* infection \[[@CR10]\] combined with at least one of general, inflammatory, hemodynamic, organ dysfunction, or tissue perfusion parameters derived from the 2001 International Sepsis Definitions Conference \[[@CR19]\]. Readmissions, admissions for elective surgery, and patients transferred from another ICU were excluded, except for patients referred to one of the study centers on the day of admission.

Biomarker measurements {#Sec4}
----------------------

All measurements were done in EDTA anticoagulated plasma obtained within 24 h after admission (day 0) and days 2 and 4. Assays are described in the online supplement. Normal biomarker values were acquired from EDTA plasma from 27 age- and gender-matched healthy volunteers, from whom written informed consent was obtained.

Statistical analysis {#Sec5}
--------------------

Data analyses were performed in R (v3.1.1). Baseline characteristics of study groups were compared with the Chi-square test for categorical variables and *t* test or Wilcoxon rank sum test for continuous variables. Mixed-effects models were executed to analyze repeated measurements. Propensity score matching and Cox proportional hazards regression analyses were performed as described in the online supplement. To account for random effects of propensity matching, appropriate tests were used in the propensity-matched cohort: paired *t* test, Wilcoxon signed-rank test, McNemar test, stratified log-rank test, and Cox frailty model. Because of missing plasma samples in both groups (discharge, death, logistics), a paired test was not suitable to compare plasma sample measurements in the matched cohort. *P* values below 0.05 were considered significant.

Results {#Sec6}
=======

Patients {#Sec7}
--------

A total of 6994 admissions were included in the MARS study from January 2011 until July 2013, of which 1483 involved an admission diagnosis of sepsis. A total of 129 transfers from other ICUs and 250 readmissions were excluded; prior use of medication could not be retrieved in 44 cases. In addition, 88 patients admitted for elective surgery were excluded. As a result, 972 patients were included for analysis (523 in AMC, 449 in UMCU), of whom 267 (27.5 %) were on chronic antiplatelet therapy prior to ICU admission. Baseline characteristics are shown in Table [1](#Tab1){ref-type="table"}. Acetylsalicylic acid was the most commonly used antiplatelet drug (95.9 %), whereas clopidogrel and dipyridamole were used by 16.1 and 12.4 % of the patients on antiplatelet therapy, respectively; 67 patients (25.1 %) were on more than one antiplatelet drug. Patients with antiplatelet therapy were older than those without, and more frequently men. As expected, cardiovascular disease was much more prevalent in antiplatelet therapy users, together with diabetes mellitus and COPD; non-users had a greater frequency of malignancies. In accordance, antiplatelet therapy users were also more frequently on other vasoactive drugs, including statins, ACE inhibitors, beta-blockers, and calcium channel blockers. Sites of infection and causative pathogens did not differ between users and non-users of antiplatelet agents (Supplemental Table 1).Table 1Baseline characteristics of unmatched and propensity-matched patientsUnmatched cohortPropensity-matched cohortAntiplatelet therapy\
*N* = 267No antiplatelet therapy\
*N* = 705*p*Antiplatelet therapy\
*N* = 150No antiplatelet therapy\
*N* = 150*p*Demographics  Age, years, mean \[SD\]67.6 \[10.4\]58.8 \[15.4\]\<0.000166.1 \[10.5\]65.7 \[10.7\]0.66  Gender, male (%)184 (68.9)402 (57)\<0.00191 (60.7)96 (64)0.61  Race, white (%)242 (90.6)617 (87.5)0.15140 (93.3)137 (91.3)0.65  BMI, kg/m^2^, mean \[SD\]26.2 \[6.2\]25.8 \[6.1\]0.4026.3 \[6.7\]26.2 \[5.9\]0.97  Admission type, medical (%)220 (82.4)564 (80)0.41124 (82.7)128 (85.3)0.64Comorbidities  Charlson score, median \[IQR\]^a^2 \[1--3\]1 \[0--2\]\<0.0012 \[1--3\]2 \[1--2\]0.31  Cerebrovascular disease (%)54 (20.2)37 (5.2)\<0.00127 (18)21 (14)0.38  Chronic cardiovascular insufficiency (%)18 (6.7)20 (2.8)0.00658 (5.3)9 (6)1  Chronic renal insufficiency (%)63 (23.6)83 (11.8)\<0.00133 (22)31 (20.7)0.88  Congestive heart failure (%)25 (9.4)21 (3)\<0.00111 (7.3)11 (7.3)1  COPD (%)62 (23.2)88 (12.5)\<0.00130 (20)37 (24.7)0.39  Diabetes mellitus (%)96 (36)109 (15.5)\<0.00145 (30)46 (30.7)1  Hematologic malignancy (%)13 (4.9)65 (9.2)0.03710 (6.7)8 (5.3)0.81  Hypertension (%)127 (47.6)175 (24.8)\<0.00160 (40)55 (36.7)0.63  Immune deficiency (%)47 (17.6)167 (23.7)0.0534 (22.7)30 (20)0.65  Liver cirrhosis (%)6 (2.2)16 (2.3)14 (2.7)3 (2)1  Metastatic malignancy (%)4 (1.5)35 (5)0.0123 (2)0 (0)0.25  Myocardial infarction (history of) (%)72 (27)20 (2.8)\<0.00115 (10)17 (11.3)0.81  Non-metastatic malignancy (%)44 (16.5)88 (12.5)0.1124 (16)20 (13.3)0.63  Peripheral vascular disease (%)68 (25.5)45 (6.4)\<0.00122 (14.7)20 (13.3)0.87Chronic medication  ACE inhibitors and ARBs (%)131 (49.1)157 (22.3)\<0.00166 (44)66 (44)1  Anticoagulants (%)33 (12.4)123 (17.4)0.0622 (14.7)26 (17.3)0.63  Beta-blockers (%)152 (56.9)166 (23.5)\<0.00171 (47.3)65 (43.3)0.50  Calcium channel blockers (%)83 (31.5)93 (13.2)\<0.00142 (28)36 (24)0.50  Corticosteroids (%)38 (14.2)114 (16.2)0.4727 (18)29 (19.3)0.87  Diuretics (%)90 (33.7)160 (22.7)0.00147 (31.3)48 (32)1  Insulin (%)57 (21.3)62 (8.8)\<0.00129 (19.3)29 (19.3)1  NSAIDs and COX II inhibitors (%)23 (8.6)89 (12.6)0.1013 (8.7)11 (7.3)0.84  Oral antidiabetic drugs (%)62 (23.2)66 (9.4)\<0.00126 (17.3)30 (20)0.66  Other antiarrhythmic drugs (%)13 (4.9)37 (5.2)0.876 (4)8 (5.3)0.79  Statins (%)182 (68.2)129 (18.3)\<0.00184 (56)86 (57.3)0.87Antiplatelet therapy  Acetylsalicylic acid (%)256 (95.9)141 (94)  Clopidogrel (%)43 (16.1)20 (13.3)  Dipyridamole (%)33 (12.4)19 (12.7)  Prasugrel (%)2 (0.7)1 (0.7)Severity of disease in first 24 h  APACHE IV score, median \[IQR\]83 \[67--107\]80 \[63--102\]0.0683 \[66--105\]83 \[64--104\]0.96  APACHE IV APS, median \[IQR\]67 \[52--90\]68 \[51--86\]0.5766 \[51--88\]68 \[49--87\]0.85  SOFA score, median \[IQR\]^b^7 \[5--9\]7 \[5--9\]0.317 \[5--10\]8 \[5--9\]0.55  Organ failure (%)228 (85.4)595 (84.4)0.50130 (86.7)125 (83.3)0.79  Shock (%)86 (32.2)239 (33.9)0.6747 (31.3)52 (34.7)0.60Treatment during first 24 h  Mechanical ventilation (%)209 (78.3)545 (77.3)0.80117 (78)113 (75.3)0.70  Renal replacement therapy (%)34 (12.7)68 (9.6)0.1916 (10.7)19 (12.7)0.72*ACE* angiotensin-converting enzyme, *APACHE* acute physiology and chronic health evaluation, *APS* acute physiology score, *ARBs* angiotensin receptor blockers, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *IQR* interquartile range, *NSAIDs* non-steroidal anti-inflammatory drugs, *SD* standard deviation, *SOFA* sequential organ failure assessment^a^Age not included in score^b^Central nervous system not included in score

Considering the large baseline differences between users and non-users of antiplatelet drugs at baseline, we constructed a propensity-matched cohort. Thus 961 patients were assigned a propensity score for receiving antiplatelet therapy (99 % of all patients included); 11 patients were not given a score as a result of missing data. As a result of the unequal distribution of propensity scores between the groups (Supplemental Fig. 1), 150 of 267 antiplatelet users could be matched to non-users. The propensity-matched patients were similar with regard to comorbidity, chronic medication, and demographic distribution (Table [1](#Tab1){ref-type="table"}).

Administration of antiplatelet therapy during ICU admission was dependent on the judgment of the medical team; at least one dose in the first 2 days of admission was received by 43.8 % of antiplatelet users in the unmatched cohort and by 40.0 % in the matched cohort.

Sepsis severity on admission {#Sec8}
----------------------------

APACHE IV and SOFA scores and the presence of organ failure and shock were similar between chronic users and non-users of antiplatelet therapy, both in the unmatched and the propensity-matched cohort analyses (Table [1](#Tab1){ref-type="table"}). Likewise, the use of supportive therapy (mechanical ventilation and renal replacement therapy) during the first 24 h after admission were similar between groups. Together these data suggest that the use of antiplatelet therapy does not influence the severity of sepsis upon admission to the ICU.

Sepsis outcomes {#Sec9}
---------------

Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"} show unadjusted outcomes of the unmatched and propensity-matched patients stratified according to the use of antiplatelet therapy. Irrespective of matching, antiplatelet therapy did not impact on the occurrence of organ failure or shock during ICU admission, or on mortality in the ICU, or at 30, 60, or 90 days. In a Cox proportional hazards model, APS was significantly associated with mortality rate at 30, 60, and 90 days in both the unmatched and matched cohort, whereas antiplatelet therapy was not. To confirm our findings, propensity scores were included in the regression model of the complete cohort, as a different method to adjust for propensity bias. Again, antiplatelet therapy was not associated with mortality, either at 30 days (Table [3](#Tab3){ref-type="table"}), 60 days (Supplemental Table 2), or 90 days (Supplemental Table 3).Table 2Outcomes of unmatched and propensity-matched patientsUnmatched cohortPropensity-matched cohortAntiplatelet therapy\
*N* = 267No antiplatelet therapy\
*N* = 705*p*Antiplatelet therapy\
*N* = 150No antiplatelet therapy\
*N* = 150*p*Length of stay ICU, median, days \[IQR\]4 \[2--9\]5 \[2--10\]0.234 \[2--9\]4 \[1--10\]0.69Organ failure during admission (%)228 (85.4)595 (84.4)0.50137 (91.3)132 (88)0.34Shock during admission (%)86 (32.2)239 (33.9)0.6759 (39.3)65 (43.3)0.54Mortality  ICU mortality (%)52 (19.5)150 (21.3)0.6031 (20.7)29 (19.3)0.88  30-day mortality (%)82 (30.7)196 (27.8)0.4447 (31.3)41 (27.3)0.63  60-day mortality (%)94 (35.2)237 (33.6)0.7152 (34.7)50 (33.3)1  90-day mortality (%)98 (36.7)263 (37.3)0.8355 (36.7)61 (40.7)0.54*ICU* intensive care unit, *IQR* interquartile range Fig. 1Impact of antiplatelet therapy on survival. Kaplan--Meier plots of survival time up to 90 days after intensive care unit admission for the unmatched (**a**) and the propensity-matched (**b**) cohorts. Differences between groups were not significant Table 3Association of antiplatelet therapy with 30-day mortality using Cox proportional hazards regression in unmatched and propensity-matched cohortUnmatched cohortPropensity-matched cohortUnmatched cohort adjusted for propensityHR95 % CI*p*HR95 % CI*p*HR95 % CI*p*Antiplatelet therapy1.050.81--1.360.691.210.79--1.840.381.220.88--1.700.23APS1.021.02--1.03\<0.00011.021.01--1.02\<0.00011.021.02--1.03\<0.0001*APS* acute physiology score, *HR* hazard ratio, *CI* confidence interval

Subgroup and sensitivity analyses {#Sec10}
---------------------------------

In addition, we compared patients with only acetylsalicylic acid therapy to antiplatelet non-users, and patients receiving more than one antiplatelet drug with antiplatelet non-users. Outcomes from these patient groups were comparable to the initial cohort (data not shown). To evaluate the association between antiplatelet therapy and mortality in patients with septic shock we performed a subgroup analysis in this subset of patients (Supplemental Table 4). In addition, we included the interaction with antiplatelet therapy in the Cox proportional hazards models of the complete cohorts (Supplemental Table 5). These analyses did not change our findings: antiplatelet therapy was not associated with altered outcome. We defined septic shock as the use of vasopressors (noradrenaline) for hypotension for more than 50 % of the ICU day \[[@CR20], [@CR21]\]. We performed additional analyses in which shock was defined as the use vasopressors for hypotension for more than 6 h. Using this shock definition, we found that antiplatelet therapy was not associated with a different outcome (Supplemental Tables 6 and 7).

Host response biomarkers {#Sec11}
------------------------

To obtain insight into the association between chronic antiplatelet therapy and hallmark host responses, we measured 19 biomarkers providing insight into activation of coagulation (platelet counts, D-dimer, protein C, antithrombin), endothelial cell activation (sE-selectin, sICAM-1, angiopoietin-1, angiopoietin-2), renal injury (creatinine, NGAL, and cystatin C), release of proinflammatory (TNF-α, IL-1β, IL-6, IL-8) and anti-inflammatory cytokines (IL-10, IL-13), and release of metalloproteinases (MMP-8 and TIMP-1) in blood obtained within 24 h after admission (day 0) and days 2 and 4. Table [4](#Tab4){ref-type="table"} shows biomarker values in the propensity-matched cohort; biomarkers measured in the unmatched cohort are provided in Supplemental Table 8. As expected \[[@CR22]\], biomarkers measured in sepsis patients differed significantly from those measured in controls (Supplemental Table 9). In the unmatched cohort platelet counts overall were higher in patients using antiplatelet therapy versus patients not on antiplatelet therapy (*p* = 0.002), in particular on days 0 and 2 of ICU admission, but this difference was not present anymore in the propensity-matched cohort. In addition, plasma creatinine was elevated in antiplatelet users at all timepoints in the unmatched but not in the matched cohort. IL-10 levels were slightly decreased in antiplatelet drug users compared to non-users, most notably on days 2 and 4; however, no significance remained in the propensity-matched cohort. Antiplatelet therapy did not alter the plasma levels of any of the other biomarkers in either the unmatched or the propensity-matched cohort.Table 4Plasma biomarkers in propensity-matched cohortDays 0, 2, 4Admission (day 0)Day 2Day 4*p* ^a^Antiplatelet therapy\
*N* = 132^b^No antiplatelet therapy\
*N* = 125*p*Antiplatelet therapy\
*N* = 110No antiplatelet therapy\
*N* = 103*p*Antiplatelet therapy\
*N* = 71No antiplatelet therapy\
*N* = 75*p*Coagulation  Platelets (×10^9^/l)0.62189 \[124--268\]178 \[123--274\]0.76179 \[128--244\]168 \[109--280\]0.65173.5 \[88--249\]164 \[85--314\]0.74  D-dimer (µg/ml)0.0811.7 \[6--19.1\]9.2 \[3.8--17.5\]0.0910.8 \[5.4--18.4\]9.4 \[3.9--18.5\]0.2813.5 \[7.7--20\]11.5 \[6.3--17.5\]0.25  Protein C (ng/ml)0.71116.3 \[93.9--150.1\]113.7 \[81.9--164.3\]0.99115.8 \[90.6--161.6\]117.5 \[88.5--172.7\]0.50126.5 \[94.2--182.4\]145.4 \[106.9--191\]0.09  Antithrombin (ng/ml)0.59726 \[493.8--1127.8\]748.6 \[549.3--1031.5\]0.71690.9 \[428.7--1037.6\]699.1 \[462.1--1048\]0.59827.8 \[566.1--1383.9\]930.6 \[587.4--1392.6\]0.55Endothelial cell activation  sE-selectin (ng/ml)0.9111.2 \[5--26.5\]11.7 \[5--25.3\]0.7912.1 \[5.3--22\]10.9 \[4.6--19.8\]0.477.6 \[4.4--16.4\]9 \[4.2--16.5\]0.83  sICAM-1 (ng/ml)^c^0.32193.3 \[116.4--334.5\]167.5 \[100.3--275.7\]0.43213 \[114.9--364.1\]201.3 \[107.9--337.8\]0.50223.2 \[139--355.1\]202.6 \[117--334.4\]0.39  Ang-1 (ng/ml)0.351.6 \[0.8--4.7\]2.6 \[1.1--5.3\]0.071.7 \[0.8--4\]1.6 \[0.8--3.5\]0.721.3 \[0.5--3.5\]1.4 \[0.7--3.8\]0.46  Ang-2 (ng/ml)0.807.7 \[3.4--16.1\]7.7 \[3.3--13.9\]0.718.3 \[3.7--20\]7.3 \[3.6--14.7\]0.305.6 \[2.5--10.8\]6.2 \[3--17.6\]0.24  Ang-2/Ang-1 ratio0.444 \[0.9--16.8\]2.6 \[1--9.2\]0.174.5 \[1.4--23.5\]4.4 \[1.8--15.3\]0.764 \[0.9--16.3\]4.8 \[1.6--17.2\]0.69Metalloproteinases  MMP-8 (ng/ml)0.304.3 \[1.4--11.3\]2.6 \[1--8.5\]0.123.8 \[1.3--8.3\]2 \[0.7--4.8\]0.011.8 \[0.7--5\]1.3 \[0.7--4\]0.36  TIMP-1 (ng/ml)0.81631 \[322.8--1027.8\]580.1 \[306.8--1129.5\]0.94517.6 \[295--876.4\]507.2 \[276.1--851.4\]0.51364.9 \[222.2--766.4\]424.9 \[220.2--693\]0.88Pro-inflammatory cytokines  TNF-α (pg/ml)0.581 \[0.7--1.7\]1.2 \[0.7--1.9\]0.211 \[0.7--1.7\]1 \[0.7--1.7\]0.960.7 \[0.7--1.7\]1.1 \[0.2--1.7\]0.21  IL1-β (pg/ml)0.892.2 \[1.1--4.5\]2.6 \[1.1--5\]0.562.3 \[1.1--3.4\]1.8 \[1--3.1\]0.501.8 \[1--3.2\]2.6 \[1.3--3.4\]0.12  IL-6 (pg/ml)0.98175.3 \[51.7--854.1\]133.7 \[32.4--1393.7\]0.3259.1 \[22.3--145.9\]64.3 \[24.5--246.1\]0.6540 \[13.1--100.1\]33.9 \[13.2--96.5\]0.94  IL-8 (pg/ml)0.81124.6 \[51.7--528.5\]107.9 \[52.1--446.2\]0.4375.7 \[28.9--181.7\]65.5 \[32.1--153\]0.9858 \[18.3--180.4\]52.3 \[20.2--130.4\]0.70Anti-inflammatory cytokines^d^  IL-10 (pg/ml)0.2913.8 \[4--56.7\]13.5 \[5.1--49.9\]0.906.3 \[2.9--13.8\]8.1 \[3.5--17.3\]0.133.9 \[1.9--9.2\]5.1 \[2--14.2\]0.28Renal injury  Creatinine (µmol/l)0.74140 \[83--234\]126 \[79--230\]0.38115 \[75--191\]111 \[70--228\]0.67106 \[66.8--167\]99 \[71--158\]0.81  NGAL (ng/ml)^e^0.54306.5 \[178.4--535\]302.3 \[155.7--562\]0.91271 \[167.8--499.6\]240.7 \[121.9--569.6\]0.43201.6 \[131.8--403.2\]209 \[117.4--395.2\]0.81  Cystatin C (µg/ml)0.721.7 \[1.1--2.5\]1.6 \[1.1--2.9\]0.661.7 \[1.1--2.6\]1.4 \[1--2.8\]0.911.6 \[1--2.4\]1.7 \[1.3--3\]0.47Plasma levels on days 0, 2, and 4 after intensive care unit admission. Results are presented as medians and interquartile ranges*Ang* angiopoietin, *IL* interleukin, *MMP* matrix metalloproteinase, *NGAL* neutrophil gelatinase-associated lipocalin, *sE*-*selectin* soluble E-selectin, *sICAM*-*1* soluble intercellular adhesion molecule-1, *TIMP* tissue inhibitor of metalloproteinase, *TNF*-*α* tumor necrosis factor-α^a^Mixed-effects models comparing antiplatelet users with non-users over time^b^Number of patients of whom plasma was available for measurement of biomarkers; platelet counts and creatinine levels were available for all patients^c^Soluble intercellular adhesion molecule-1 also originates from leukocytes^d^Levels of the anti-inflammatory cytokine IL-13 were below detection limit of the assay in the vast majority of patients and not different between groups (data not shown)^e^NGAL levels can also be elevated in sepsis as a consequence of leukocyte activation

Discussion {#Sec12}
==========

Platelet activation has been implicated as an important component of the deregulated host response in sepsis, and accordingly, antiplatelet therapy exerted protective effects in preclinical sepsis models \[[@CR4], [@CR8]\]. We here analyzed a prospectively enrolled cohort of 972 well-defined patients with sepsis and did not find an association between chronic antiplatelet therapy and severity of illness upon ICU admission, mortality, or biomarkers indicative of key host responses to severe infection. These data strongly argue against a beneficial effect of pre-existing antiplatelet therapy on sepsis severity or outcome in critically ill patients.

Four earlier retrospective studies investigated the effect of chronic antiplatelet therapy on mortality of patients with sepsis, severe sepsis, and septic shock, reporting variable results \[[@CR9], [@CR23]--[@CR25]\]. One study entailed patients admitted to a medical ICU with severe sepsis or septic shock, and it found no impact of chronic antiplatelet therapy after adjusting for the propensity to receive antiplatelet therapy and severity of illness as calculated by APACHE III score \[[@CR23]\]. The other investigation encompassed patients admitted to the ICU with a systemic inflammatory response syndrome (SIRS), of which a subgroup was classified as sepsis; propensity analysis showed a reduction in mortality in acetylsalicylic acid users in both the overall SIRS population and the sepsis subgroup \[[@CR25]\]. While both studies adjusted for concurrent statin use in their propensity analyses, other chronic medication use was not taken into account \[[@CR23], [@CR25]\]. The third study performed regression analysis to establish the effect of chronic antiplatelet medication on sepsis outcome and reported an association between low-dose acetylsalicylic acid therapy with decreased ICU or hospital mortality \[[@CR24]\]. Another report investigated the continuous use of acetylsalicylic acid during ICU stay and reported results similar to the previously mentioned study \[[@CR26]\]. A very recent investigation used a medical claims database to report an association between chronic antiplatelet treatment and a reduced sepsis mortality \[[@CR9]\]. Our study is different from these previous reports in several aspects. Most importantly, we prospectively enrolled patients and classified patients as having sepsis on the basis of strict diagnostic criteria. In addition, we performed propensity matching which enabled us to create comparable cohorts with respect to many important patient characteristics.

While platelets have been implicated in multiple inflammatory and procoagulant reactions, and thereby in the development of sepsis complications such as microvascular dysfunction, disseminated intravascular coagulation, and multiple organ failure \[[@CR2], [@CR4]--[@CR6]\], knowledge of the effect of antiplatelet therapy on the host response to sepsis in patients is highly limited. Critically ill patients on acetylsalicylic acid had higher plasma fibrinogen levels in one study \[[@CR24]\], which is difficult to interpret since fibrinogen is essential for fibrin formation and thus coagulation, but is also an acute phase protein. We measured 19 biomarkers indicative of important host response to sepsis on admission to the ICU, and at days 2 and 4. In the unmatched cohort we found some evidence of reduced platelet activation in patients on antiplatelet drugs, as reflected by higher platelet counts. However, the difference between users and non-users was not present anymore in the propensity-matched cohort. Besides their role in primary hemostasis, platelets facilitate activation of the coagulation system by assembling coagulation factor complexes on their surface and catalyzing the generation of thrombin \[[@CR27]\]. In addition, platelets can enhance endothelial cell activation during sepsis via CD40 ligand on their cell membrane and platelet-secreted microparticles \[[@CR4]\]. Nonetheless, we did not find any evidence for an effect of antiplatelet therapy on coagulation or endothelial cell activation in our study. Platelets can release several cytokines from their α-granules \[[@CR6]\], and platelets can form complexes with leukocytes, thereby influencing leukocyte effector functions and cytokine secretion \[[@CR28]--[@CR30]\]. In accordance, long-term clopidogrel treatment was associated with reduced TNF-α and IL-13 levels in patients with cardiac disease undergoing non-emergent stenting \[[@CR31]\] and several antiplatelet agents were shown to inhibit intracellular leukocyte TNF-α and IL-8 responses upon acute stroke \[[@CR32]\]. However, in the current investigation antiplatelet therapy was not associated with statistically significant differences in the plasma levels of pro-inflammatory cytokines in patients with sepsis. Moreover, antiplatelet therapy was not associated with alterations in MMP-8 or TIMP-1 levels, which were previously described to be elevated in patients with sepsis \[[@CR33]\] and have been suggested to contribute to many inflammatory reactions during severe infection \[[@CR34]\]. The similarity of biomarkers in antiplatelet users and non-users does not corroborate with the results from many preclinical studies showing benefit from antiplatelet therapy during infection or inflammation \[[@CR4], [@CR8]\]. Even in our well-defined cohort, sepsis patients are heterogeneous in terms of site and microbiology of the infection, disease severity, genetic background, age, and comorbidity, and plasma biomarker concentrations demonstrated a large inter-individual variability, which may explain the lack of effect by antiplatelet therapy. In addition, the dose at which antiplatelet therapy is administered to patients may be insufficient to alter the strong inflammatory and procoagulant responses induced by severe sepsis.

A strength of our study is the prospectively enrolled cohort in which patients were meticulously classified and followed daily. We performed propensity matching, which enabled us to specifically evaluate the effect of antiplatelet therapy, by catering for differences in baseline characteristics between users and non-users. Nonetheless, it remains possible that a bias remained as a result of unmeasured confounders, an important limitation of propensity score analyses. Considering that after propensity matching 150 patients per group remained to evaluate differences between those who did and those who did not use chronic antiplatelet therapy, the possibility of false negative results exists. However, the number of patients needed in the propensity-matched analysis to detect a statistically significant difference between groups with a power of 80 % would be more than 2000 per group for mortality and from more than 330 to more than 150,000 per group for individual biomarkers. While these numbers are difficult to achieve, they also raise doubt about the clinical and biological relevance of potential differences not revealed in our analyses. Additional limitations are the lack of information about the indication for, dosing of, and adherence to antiplatelet therapy; the lack of information about bleeding complications; and the fact that this study was performed in two centers in the Netherlands and may not reflect general ICU practice. Also, we were not able to investigate whether chronic antiplatelet therapy influences sepsis progression before ICU admission; with the current study we cannot rule out that antiplatelet therapy has beneficial effects in early stages of sepsis.

Conclusion {#Sec13}
==========

In this prospectively assembled cohort of 972 well-defined patients with sepsis we did not find an association between chronic antiplatelet therapy and severity of illness or outcome. Additionally, no differences in biomarkers indicative of key host responses to sepsis were found between patients who did and who did not receive chronic antiplatelet therapy. Our data strongly argue against a beneficial effect of pre-existing antiplatelet therapy on sepsis severity or outcome.
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